Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Funds and ETFs Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
11.87 USD -0.84% Intraday chart for Zentalis Pharmaceuticals, Inc. +5.32% -21.65%
May. 29 Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors CI
May. 24 Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial MT

ETFs positioned on Zentalis Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.11% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.09% 0 M€ 0.00% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.07% 2 M€ -.--%
SECTOR ROTATION ETF - USD ETF Sector Rotation ETF - USD
0.04% 1,487 M€ +7.77% -
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD ETF SPDR MSCI World Small Cap UCITS ETF - USD
0.03% 746 M€ -.--% -
ARMOR US EQUITY INDEX ETF - USD ETF Armor US Equity Index ETF - USD
0.02% 9 M€ -.--% -
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD ETF Adaptive RH Tactical Outlook ETF - USD
0.00% 9 M€ +9.86% -
RAREVIEW SYSTEMATIC EQUITY ETF - USD ETF Rareview Systematic Equity ETF - USD
0.00% 45 M€ -.--% -
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD ETF Adaptive RH Hedged Multi-Asset Income ETF - USD
0.00% 17 M€ +4.00% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +3.86% -

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Sector
Biotechnology & Medical Research
Calendar
02:30pm - American Society of Clinical Oncology Meeting - Abstract No 11525
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.88 USD
Average target price
33.4 USD
Spread / Average Target
+181.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZENTALIS PHARMACEUTICALS, INC. Stock Zentalis Pharmaceuticals, Inc.
-21.65% 843M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. Funds and ETFs Zentalis Pharmaceuticals, Inc.